Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.

CONCLUSIONS: This 24-week, comparative, clinical trial in patients on hemodialysis with ESKD and anemia demonstrated there is no clinically meaningful difference in efficacy or safety between epoetin alfa-epbx and epoetin alfa.
PMID: 29921734 [PubMed - as supplied by publisher]

Source: Clinical Journal of the American Society of Nephrology : CJASN - June 19, 2018 Category: Urology & Nephrology Authors: Fishbane S, Singh B, Kumbhat S, Wisemandle WA, Martin NE Tags: Clin J Am Soc Nephrol Source Type: research